Integrated BioTherapeutics, Inc. (IBT) is a biotechnology company focused on the discovery of novel vaccines and therapeutics for emerging infectious diseases. IBT’s pipeline includes promising product candidates for bacterial and viral infections. IBT’s bacterial program is focused on countermeasures vs. staphylococcal infections, primarily by targeting a variety of toxins produced by S. aureus. IBT’s antiviral pipeline includes unique pan-filovirus antibody candidates, vaccines and a variety of other product candidates for emerging viruses.
Located in Rockville, Maryland, IBT has a close working relationship with United States Government agencies including the National Institute of Allergy and Infectious Diseases (NIAID/NIH), National Cancer Institute (NCI), Department of Defense (DOD), United States Army Medical Research Institute of Infectious Diseases (USAMRIID), and many biotechnology and pharmaceutical companies and academic laboratories.
In addition to the active anti-infective discovery pipeline at IBT, we also operate a CRO business called IBT Bioservices which provides state of the art infectious disease discovery and animal model testing services to industrial and academic clients.